These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32316005)

  • 21. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
    Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
    Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
    Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastritis cystica profunda is associated with aberrant p53 and Epstein-Barr virus in gastric cancer: A clinicopathological, immunohistochemical and in situ hybridization study.
    Itami H; Morita K; Nakai T; Uchiyama T; Sugimoto S; Sasaki S; Matsuoka M; Myojin T; Nitta Y; Okabe F; Fujii T; Hatakeyama K; Mitoro A; Sho M; Ohbayashi C
    Pathol Int; 2021 Jan; 71(1):42-50. PubMed ID: 33084164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
    Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
    Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
    Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
    Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
    Nakano H; Saito M; Nakajima S; Saito K; Nakayama Y; Kase K; Yamada L; Kanke Y; Hanayama H; Onozawa H; Okayama H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Goto A; Kono K
    Sci Rep; 2021 Jan; 11(1):1982. PubMed ID: 33479394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
    Mishima S; Kawazoe A; Nakamura Y; Sasaki A; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Tsuji A; Shitara K
    J Immunother Cancer; 2019 Jan; 7(1):24. PubMed ID: 30704511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.
    Sun Q; Fu Y; Chen X; Li L; Wu H; Liu Y; Xu H; Zhou G; Fan X; Xia H
    Gut Liver; 2022 Nov; 16(6):875-891. PubMed ID: 35611665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
    Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
    Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer.
    Sun Y; Yu W; Guan W; Cai L; Qiao M; Zheng L; Jiang R; Wang R; Wang L
    Cancer Manag Res; 2019; 11():6397-6410. PubMed ID: 31372044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
    Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
    BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study.
    Beer A; Taghizadeh H; Schiefer AI; Puhr HC; Karner AK; Jomrich G; Schoppmann SF; Kain R; Preusser M; Ilhan-Mutlu A
    Pathol Oncol Res; 2020 Oct; 26(4):2225-2235. PubMed ID: 32372174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma.
    Setia N; Ahn S; Han HS; Park DY; Lauwers GY
    Hum Pathol; 2019 Dec; 94():64-70. PubMed ID: 31676362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
    Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
    Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
    Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
    Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
    Kim JY; Park CK; Noh S; Cheong JH; Noh SH; Kim H
    Gut Liver; 2023 Sep; 17(5):753-765. PubMed ID: 36789575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.